EN
In Germany, uterine cancer is treated in gynaecological oncology departments, and the plan covers more than the tumour. A diagnosis involving the uterus is rarely a medical matter alone: it brings questions about the body, the future and sometimes having children. At home these questions are often left out of the conversation; German gynaecological oncology treats them as part of the plan.
The first step is to establish which tumour this is and how far it has spread. Uterine cancer treatment in Germany starts from that answer, which decides whether surgery is needed and what is added to it. This page explains how the diagnosis is confirmed, which methods are used and when organ-sparing surgery is possible.
What patients usually arrive with
Most women come because of bleeding outside the cycle or after the menopause, or changes found at an examination and in a smear. “Cancer of the uterus” covers different diseases: most often cancer of the body of the uterus (the endometrium) or cancer of the cervix, and the approaches differ.
By then a woman usually has some results, but it is not always clear which tumour is involved and how far it has spread — and everything that follows depends on that. Readers with a cervical diagnosis will find more on the page about cervical cancer treatment.
How the diagnosis is confirmed in Germany
The diagnosis rests on tissue: no treatment plan is made until a pathologist has examined it. In cervical cancer a targeted biopsy is taken during colposcopy, a magnified view of the cervix, sometimes with conisation — removal of a small cone-shaped piece, which also confirms the diagnosis. In cancer of the uterine body, endometrial tissue is obtained by hysteroscopy (a camera look inside the uterus) and curettage. The pathologist determines the tumour type and grade and, where needed, molecular features. If the biopsy was done at home, a German pathologist reviews the slides and blocks already taken. Each step is covered on the page about uterine cancer diagnosis.
To see how far the disease extends, doctors use examination, ultrasound (including transvaginal), pelvic MRI and CT. MRI shows soft tissue particularly well, so it is usually the main method for judging how deeply the tumour has grown into the uterine wall or the tissue around the cervix. CT looks for lesions beyond the pelvis, and PET scanning is added where needed.
A separate question is whether the lymph nodes are involved. In many cases the sentinel node — the one the lymph from the tumour drains to first — is located and examined; if it is clear, the other nodes are usually left in place, so nothing is removed unnecessarily. The result is a precise picture of which cancer this is and how early or advanced it is. An English patient guide is the article on endometrial cancer prepared with the Cancer Information Service of the German Cancer Research Center.
Methods used
Uterine cancer treatment in Germany is matched to the tumour type and stage rather than to a general scheme. Surgery is usually the basis — from organ-sparing procedures in early disease to removal of the uterus, whose extent depends on the type and spread of the tumour. The page on surgery for uterine cancer explains the operation.
Many operations are done through small ports — laparoscopically and, in some centres, with a robotic system — which usually means less trauma and a faster recovery. But for some tumours open surgery remains the better choice: in cervical cancer, studies have shown a somewhat higher risk of recurrence after laparoscopic surgery, so the operation is usually done through an abdominal incision. The robot is the surgeon’s tool, not a separate treatment.
A separate conversation, important to many women, concerns fertility: in some early tumours in young patients, organ-sparing options are discussed. In very early cervical cancer, conisation or trachelectomy (removing the cervix but keeping the body of the uterus) may be enough; pregnancy is then possible, with a higher risk of miscarriage and premature birth. In a very early hormone-sensitive tumour of the uterine body, surgery can be postponed in favour of high-dose progestins, progesterone-like hormones, with regular checks of the endometrium; once family planning is complete, removing the uterus is recommended. This is decided case by case after exact diagnosis, by the tumour board with the patient, but in Germany the question is at least raised openly.
Around the operation, other methods are added as indicated: external radiotherapy and brachytherapy, in which the source is brought right to the tumour from inside and acts locally; chemotherapy for advanced disease or a high risk of recurrence; hormone therapy for hormone-sensitive tumours of the uterine body; targeted drugs or immunotherapy for some tumours. The tumour board, not a single doctor, decides what a case needs. Treatment follows approved protocols — for cancer of the uterine body, the national guideline in the AWMF register — and within that reasoned frame the gynaecological oncologist, surgeon, radiation oncologist and pathologist choose the plan together.
If the tumour has spread or come back
Treatment exists both for advanced disease and for recurrence; its aim is to hold the disease back and preserve quality of life. The basis is chemotherapy, for some tumours combined with immunotherapy; which drugs fit depends on the molecular type of the tumour, for example on whether its DNA repair system (mismatch repair, MMR) is defective. Hormone-sensitive tumours receive hormone therapy. Radiotherapy is added where indicated, including to relieve pain or bleeding, and sometimes surgery removes individual lesions.
For a patient treated at home first, the tumour board starts by reviewing the discharge letters, images and tissue; missing molecular tests are usually done on the existing blocks. Pain relief, nutrition and psychological support belong to the plan from the first day, not to a “last stage”.
When a second opinion makes sense
A second opinion makes sense when the diagnosis was made at home but doubts remain — above all when the choice is between keeping the organ and a wider operation. The German specialist reviews the tissue and images and says plainly whether they confirm the diagnosis and agree with the plan. Details are on the page about a second opinion from a German doctor.
Send the pathology report, the histology slides or paraffin blocks, MRI and CT images on a disc and the discharge letters. A remote opinion shows whether the direction is right, but it does not replace an examination on site.
Frequently asked questions
Can uterine cancer be treated without surgery?
Sometimes, but only a doctor can decide this after a full work-up. In cervical cancer that has spread further, the basis is usually radiotherapy combined with chemotherapy rather than surgery. In cancer of the uterine body, radiotherapy alone is considered when surgery is not possible for health reasons. In a very early tumour in a young woman who wants children, surgery may be postponed in favour of hormone treatment under close monitoring.
Is pregnancy possible after treatment for uterine cancer?
In some cases, yes — if the tumour is found very early and the uterus can be kept. In the earliest cervical cancer, conisation or trachelectomy may be enough; pregnancy is then possible, though with a higher risk of miscarriage and premature birth. In a very early hormone-sensitive tumour of the uterine body, surgery is postponed during progestin treatment, and once family planning is complete, removing the uterus is recommended. So mention plans for children before treatment starts.
Is radiotherapy or chemotherapy needed after surgery?
It depends on the risk of the disease coming back. In cancer of the uterine body that is early, not aggressive and has not grown deeply into the uterine wall, further treatment is often unnecessary. Brachytherapy mainly lowers the risk of a recurrence in the vagina, while chemotherapy is used for advanced disease or a high risk.
How AlenMed arranges treatment
AlenMed handles the organisation, while such tumours are managed in gynaecological oncology departments — for example the Clinic for Gynaecology and Gynaecological Oncology at Bonn University Hospital, headed by Prof. Alexander Mustea, the University Women’s Clinic in Tübingen, led by Prof. Sara Brucker, and the gynaecological cancer centre at the Red Cross Clinic in Munich, headed by Prof. Martin Pölcher. AlenMed works with 86 partner hospitals in 38 cities and 345 doctors, and the company’s office is in Munich.
The company translates medical records, books appointments, provides the visa invitation, meets patients on arrival and supplies a medical interpreter at appointments and on the ward. The clinic issues the cost estimate in the patient’s name, and payment goes directly to the clinic; the page on uterine cancer treatment costs shows what the bill consists of.
This material is for information only, is not an offer of services and does not replace a consultation with a doctor. Whether treatment is possible, what it involves and what it can achieve is determined only after an in-person examination at the clinic.
News on this topic
Charité treats first beta-thalassemia patient with CRISPR
At Berlin Charité, a 19-year-old beta-thalassemia patient became the first in Germany to receive the newly approved CRISPR gene therapy Exagamglogene Autotemcel.
Real-World Breast Cancer Study Confirms High Five-Year Survival Rates in Germany
A landmark study of over 43,000 German patients reveals a five-year invasive disease-free survival rate of 82.9 percent in early hormone receptor-positive breast cancer.
FDA Approves Jülich Diagnostic Radiotracer FET for Brain Tumor Imaging
The FDA approves the diagnostic radiotracer FET (Pixclara®) for evaluating brain gliomas, highlighting decades of neuro-oncology research at Forschungszentrum Jülich.
